



HOT TOPIC

Posted on 11.30.2020

CHANGE OF DOSAGE FOR CPT C9066

CMS has issued a change to the long description for the medical injectable drug Trodelvy HCPCS, C9066 as follows: INJECTION, SACITUZUMAB GOVITECAN-HZIY, 2.5MG.

Effective **October 1, 2020**, this change reflects an update to the dosage, previously 10mg to 2.5mg. Highmark will be following CMS guidelines and will only accept claims with the appropriate 2.5mg dosage.